FDA greenlights giredestrant-everolimus duo for ESR1-mutated breast cancer
The FDA approved giredestrant, branded Wilserdly, with everolimus on Nov 16 for adults with ESR1-mutated advanced breast cancer, landing four weeks before its goal date. The Genentech oral drug's evERA trial posted a progression-free survival hazard ratio of 0.38 in the 207-patient ESR1-mutant subgroup. FoundationOne Liquid CDx got companion diagnostic clearance.
- Original source: casrai.org.
- The source published it on Nov 16, 2026 at 4:00 PM.
- No second outlet has reported it yet. Treat it as a single-source claim.
The green light covers adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, with the mutation confirmed by an FDA-authorized test. Patients must have recurred during or after endocrine-based adjuvant therapy, or progressed on at least one endocrine-based regimen in the metastatic setting. FDA also authorized FoundationOne Liquid CDx as the companion diagnostic for spotting those ESR1 mutations.
The evidence comes from evERA Breast Cancer, registered as NCT05306340, a randomized, open-label, multicenter trial that enrolled 373 adults. Of them, 207 had tumors carrying ESR1 mutations. Participants got either giredestrant or physician-selected endocrine therapy — exemestane, fulvestrant or tamoxifen — and both arms also received everolimus.
Investigator-assessed progression-free survival by RECIST version 1.1 was the primary outcome. In the ESR1-mutated population, the hazard ratio came in at 0.38, with a 95% confidence interval of 0.27–0.54 and a p value below 0.0001. FDA called the overall survival data immature at that analysis; overall survival and objective response rate were listed as additional outcomes.
STAT's Andrew Joseph, writing Nov 16, called it an important regulatory decision for Roche and described giredestrant as a selective estrogen receptor degrader, framing the ESR1 mutation around resistance to standard endocrine treatments. OncLive's Ashling Wahner, in her Nov 16 report, spotlighted the companion diagnostic and the ESR1-mutated subgroup behind the decision. FDA says circulating tumor DNA was assessed centrally with FoundationOne Liquid CDx, limited to specified mutations in the receptor's ligand-binding domain.
The application ran through Project Orbis, the FDA Oncology Center of Excellence framework for concurrent international review, with FDA collaborating with Health Canada and Israel's Ministry of Health. FDA notes that Orbis participation doesn't establish authorization in any other jurisdiction, and says partner-agency applications may still be in submission or under review. This review used the agency's Assessment Aid, and full prescribing information is headed for Drugs@FDA.
TopicsFDA · Genentech · Roche · giredestrant · everolimus · FoundationOne Liquid CDx · Health Canada · Israel's Ministry of Health
Source: casrai.org
Written by AI from verified reporting.

